CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
- Resource Type
- article
- Authors
- Xinyuan Liu; Juanjuan Zhao; Xiangqian Guo; Yongping Song
- Source
- Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-4 (2023)
- Subject
- Non-Hodgkin's lymphoma
Bispecific antibody
CD20
CD3
EPCORE NHL-1
Diseases of the blood and blood-forming organs
RC633-647.5
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 1756-8722
Abstract Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).